利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.025 秒)

    Insulation displacement electrical connector with improved strain relief
    2.
    发明授权
    Insulation displacement electrical connector with improved strain relief 失效
    绝缘位移电连接器，具有改善的应力消除

    公开(公告)号：US5586905A

    公开(公告)日：1996-12-24

    申请号：US146384

    申请日：1993-11-01

    申请人： Robert C. Marshall ,  Frank Pansari, Jr.

    发明人： Robert C. Marshall ,  Frank Pansari, Jr.

    IPC分类号： H01R4/24 ,  H01R13/58

    CPC分类号： H01R4/2454 ,  H01R4/2433

    摘要： An electrical connector assembly is provided for terminating an insulated electrical wire. The assembly includes a housing having a wire-receiving opening adapted to receive the insulated electrical wire. The housing is defined by two housing halves which are relatively movable between an open condition for insertion of an insulated wire into the opening and a closed condition. A terminal is mounted on the housing and has an insulation displacement slot positioned in the opening adapted to displace the insulation of the wire and electrically engage an inner conductor of the wire. Opposing flexible portions of the housing halves provide strain relief to the insulated electrical wire by gripping the wire substantially entirely thereabout when the housing halves are in their closed condition.

    摘要翻译： 提供电连接器组件用于终止绝缘电线。 组件包括具有适于容纳绝缘电线的线接收开口的壳体。 壳体由两个壳体半部限定，两个半壳体在用于将绝缘电线插入开口的打开状态和闭合状态之间可相对移动。 端子安装在壳体上，并且具有定位在开口中的绝缘移动槽，其适于移动线的绝缘并电连接导线的内导体。 外壳半部的相对的柔性部分通过在外壳半部处于其闭合状态时基本上完全夹紧导线来为绝缘电线提供应变消除。

    Method of treating incontinence
    3.
    发明授权
    Method of treating incontinence 失效
    治疗失禁的方法

    公开(公告)号：US06987107B2

    公开(公告)日：2006-01-17

    申请号：US10055663

    申请日：2002-01-23

    申请人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson

    发明人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson

    IPC分类号： A61K31/44

    CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

    摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

    摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（N 1 O）/去甲肾上腺素（KI）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀等 优选光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

    Technique for the growth of compositionally ungraded single crystals of solid solutions
    4.
    发明授权
    Technique for the growth of compositionally ungraded single crystals of solid solutions 失效
    用于固体溶液组成不分级单晶生长的技术

    公开(公告)号：US4602979A

    公开(公告)日：1986-07-29

    申请号：US731744

    申请日：1985-05-07

    申请人： Robert C. Marshall ,  John K. Kennedy ,  Charles S. Sahagian

    发明人： Robert C. Marshall ,  John K. Kennedy ,  Charles S. Sahagian

    IPC分类号： C30B15/02 ,  C30B15/10

    CPC分类号： C30B15/10 ,  C30B15/02

    摘要： This invention describes a modified method of growing high purity, compositionally ungraded, single crystals of multicomponent solid solutions by the Czochralski, Kyropoulos, Bridgman or other related melt growth technique. In the method of this invention, the container or crucible used to contain the multicomponent crystal growing melt is fabricated from the higher melting point component of the multicomponent melt while lower melting point components are positioned within the crucible. The temperature of the crucible is then raised beyond the melting point of the lower melting point component to a temperature which is the exact melting point of the solid solution, or crystal alloy desired. This will dissolve an amount of the crucible material (higher melting point component) equal to the exact amount required to produce a solid solution having the desired composition. A seed is then introduced into the melt and normal crystal pulling is initiated resulting in the growth of a compositionally ungraded crystal having a uniform compositional content throughout its structure.

    摘要翻译： 本发明描述了通过Czochralski，Kyropoulos，Bridgman或其它相关的熔融生长技术生长高分子多组分固溶体的高纯度，组成未分级的单晶的改进方法。 在本发明的方法中，用于容纳多组分晶体生长熔体的容器或坩埚由多组分熔体的较高熔点组分制成，而较低熔点组分位于坩埚内。 然后将坩埚的温度升高到低熔点组分的熔点以上至所需固溶体或晶体合金的精确熔点的温度。 这将溶解一定量的坩埚材料（较高熔点成分）等于产生具有所需组成的固溶体所需的精确量。 然后将晶种引入熔体中，引发正常的晶体拉伸，导致其整个结构具有均匀组成含量的组成未分级晶体的生长。

    Highly selective norepinephrine reuptake inhibitors and methods of using the same
    5.
    发明授权
    Highly selective norepinephrine reuptake inhibitors and methods of using the same 失效
    高选择性去甲肾上腺素再摄取抑制剂及其使用方法

    公开(公告)号：US07723334B2

    公开(公告)日：2010-05-25

    申请号：US11928917

    申请日：2007-10-30

    申请人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    发明人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    IPC分类号： A61K31/5375 ,  A61P25/22 ,  A61P25/24 ,  A61P25/32 ,  A61P3/04

    CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

    摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

    摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（Ki）/去甲肾上腺素（Ki）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀，更优选为瑞波西汀的光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

    METHOD OF TREATING ATTENTION DEFICIT DISORDER
    8.
    发明申请
    METHOD OF TREATING ATTENTION DEFICIT DISORDER 审中-公开
    治疗缺陷性疾病的方法

    公开(公告)号：US20090247528A1

    公开(公告)日：2009-10-01

    申请号：US12430244

    申请日：2009-04-27

    申请人： Erik H.F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    发明人： Erik H.F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    IPC分类号： A61K31/5375 ,  A61P25/00

    CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

    摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

    摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（Ki）/去甲肾上腺素（Ki）的药理学选择性的化合物。该化合物的实例包括瑞波西汀，更优选为瑞波西汀的光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

    Method of treating chronic pain
    10.
    发明授权
    Method of treating chronic pain 失效
    治疗慢性疼痛的方法

    公开(公告)号：US06703389B2

    公开(公告)日：2004-03-09

    申请号：US10020261

    申请日：2001-12-14

    申请人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    发明人： Erik H. F. Wong ,  Saeeduddin Ahmed ,  Robert C. Marshall ,  Robert McArthur ,  Duncan P. Taylor ,  Lars Birgerson ,  Pasquale Cetera

    IPC分类号： A61K31535

    CPC分类号： A61K31/5375 ,  A61K31/00 ,  A61K31/537

    摘要： Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

    摘要翻译： 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（Ki）/去甲肾上腺素（Ki）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀，更优选为瑞波西汀的光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。